Strategic Agreement signed with Epilepsy Action Australia
Filed with ASX · · 2 pages · English
Earlier from Argent Biopharma
- Appendix 4E and Audited 2016 Financial Report
- Psoriasis and Acne Tests Advancing Ahead of Product Launch
- Sale of Lingokoto and Bouroubourou Gold Exploration Assets
- Leading Epilepsy Expert Joins MXC Strategic Advisory Board
- First Revenues Received from Californian Cosmetics Deal
Later from Argent Biopharma
- New Med Cannabis White Paper Developed with Uni of Sydney
- Operations Update - Multiple Revenue Streams Imminent
- September Quarter Activity and Cashflow Report
- EU Registration Commenced for CBD Derma Product Sales
- Cleansing Prospectus
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma